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Abstract: Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome 
(PMS). Pharmacologic options studied for treating severe PMS and PMDD may include selec-
tive serotonin reuptake inhibitors, anxiolytic agents, gonadotropin-releasing hormone agonists 
and the diuretic spironolactone. However, the use of combined oral contraceptives (COC) 
may be a therapeutic option in treating PMS and PMDD. The combination of drospirenone 
with ethinylestradiol (EE/drospirenone) was approved for marketing as an oral contraceptive 
in Europe and the United States. The preparation is characterized by a high contraceptive 
efficacy in combination with excellent cycle control, good tolerability, and a favourable 
impact on lipid and glucose metabolism. Recently, some placebo-controlled, randomized 
studies have tested clinical efficacy and tolerability of this COC in the treatment of 
PMDD. The aim of the present review was to elucidate the possible benefits or disadvan-
tages of PMDD treatment with this novel formulation of EE/drospirenone. The results of 
trials evaluating the use of EE/drospirenone combination in the treatment of PMDD are 
encouraging but further studies are needed. However, the reported clinical efficacy and 
the relative good tolerability of EE/drospirenone may contribute to widen the therapeutic 
spectrum of PMDD.
Keywords: Premenstrual dysphoric disord©er, oral contraceptives, drospirenone, ethinylestra-
diol, efﬁ  cacy, tolerability.
Introduction
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome 
(PMS). The essential symptoms are markedly depressed mood, appreciable anxiety, 
pronounced affective swings, and decreased interest in activities. For a precise deﬁ  ni-
tion of the syndrome these symptoms should have regularly occurred during the last 
week of the luteal phase in most menstrual cycles during the past year. They should 
also remit within a few days of the onset of menses (follicular phase) and are always 
absent in the week following menses (Endicott et al 1999). A change in symptoms 
from the follicular to the luteal phase of at least 50% is suggested for the diagnosis of 
PMDD (Steiner and Born 2000).
While majority of women regularly experience some degree of symptomatology 
during the premenstrual or late luteal phase of their reproductive cycles some 
menstruating women meet diagnostic criteria for PMDD (Johnson et al 1988). Early 
descriptions of premenstrual syndrome by Frank (1931) have now evolved into a 
diagnostic category that has striking similarities to major depression. The diagnostic 
criteria for PMDD are found in the appendix of the diagnostic and statistical manual 
of mental disorders, 4th ed. (DSM-IV) (APA 1994) and are also listed in the text as 
“depressive disorder not otherwise speciﬁ  ed.” Therapeutics and Clinical Risk Management 2007:3(4) 586
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Epidemiologically, PMDD seems to be less common 
than PMS, with 12-month prevalence rates of 3%–8% 
(Angst et al 2001; Wittchen et al 2002), and differs from 
PMS in that mood symptoms predominate over somatic 
complaints, overall symptoms are severe, and functional 
impairment is pronounced (Steiner and Born 2000). 
However, the diagnosis (and conversely the differential 
diagnosis) may be not so simple. As speciﬁ  ed, a diagnosis 
of PMDD requires documentation with prospective charting 
of mood, behavioural, and physical symptoms for at least 
two consecutive menstrual cycles in order to establish the 
cyclic nature of symptoms and to exclude a premenstrual 
exacerbation of an underlying psychiatric or organic 
disorder (Frackiewicz and Shiovitz 2001).
Some instruments may help the diagnostic process and 
are used in clinical trials; these include the daily record of 
severity of problems (DRSP), the premenstrual record of 
impact and severity of menstruation (PRISM), the calendar 
of premenstrual experiences (COPE), the daily symptom 
report (DSR) and the use of visual analogue scales (VAS) 
(Futterman and Rapkin 2006). As an alternative to formal 
rating scales, patients may keep an informal diary of 
symptoms throughout the month (Steiner et al 1999).
Pharmacologic options studied for treating severe 
PMS and PMDD may include selective serotonin reuptake 
inhibitors (SSRIs), anxiolytics, gonadotropin-releasing 
hormone (GnRH) agonists and the diuretic spironolac-
tone. The US food and drug administration (FDA) (2002) 
has labelled ﬂ  uoxetine (Sarafem), sertraline (Zoloft) and 
paroxetine (Paxil CR) for the treatment of PMDD. The 
ACOG (2000) recommends SSRIs as initial drug therapy 
in women with severe PMS and PMDD (Evidence level C, 
expert/consensus guidelines). To date, SSRI are considered 
to be the gold-standard in the treatment of this disorder 
(Freeman 2004).
However, the use of combined oral contraceptives (COC), 
in particular containing a combination of drospirenone and 
ethinylestradiol, may be a therapeutic option in treating 
PMS and PMDD. The combination of drospirenone with 
ethinylestradiol (EE/drospirenone) was recently approved for 
marketing as an oral contraceptive in Europe and the United 
States. The preparation is characterized by a high contracep-
tive efﬁ  cacy in combination with excellent cycle control, good 
tolerability, and a favourable impact on lipid and glucose 
metabolism (Parsey and Pong 2000).
The aim of the present review was to elucidate the pos-
sible beneﬁ  ts or disadvantages of PMDD treatment with this 
novel formulation of EE/drospirenone.
Pharmacological characteristics
of EE/drospirenone combination 
and its potential beneﬁ  ts 
in premenstrual symptoms
The progestin drospirenone is derived from 17a-spiro-
lactone and its pharmacological profile more closely 
resembles that of natural progesterone compared to other 
progestins (Oelkers 2004). Drospirenone acts by binding 
to aldosterone receptors, blocking aldosterone action in 
the kidneys, resulting in a substantial rise in sodium and 
water excretion and some retention of potassium. Therefore, 
drospirenone can counteract estrogen-induced stimulation 
of the renin-angiotensin-aldosterone system that can lead 
to sodium and water retention and symptoms such as breast 
tenderness and oedema: This effect may be useful in the 
treatment of patients with PMDD (Parsey and Pong 2000). 
Clinical studies with EE/drospirenone have shown it to 
have reliable contraceptive effects and a good safety proﬁ  le 
(Huber et al 2000; Parsey and Pong 2000). The 3-mg dose 
of drospirenone has been shown to be equivalent to 25 mg 
of spironolactone. Other effects include improved acne 
and other skin-related problems, which are in part related 
to the anti-androgenic activity of drospirenone (van Vloten 
et al 2002).
Concerning premenstrual symptoms, Foidart and 
colleagues (2000) reported that they were lower in women 
using drospirenone/30EE compared with desogestrel/ethi-
nylestradiol. In addition, Apter and colleagues (2003) 
conducted an open study of 336 women to evaluate the 
actions of 30EE/drospirenone on ﬂ  uid-related symptoms 
during the luteal phase of the cycle and the effects of 
these symptoms on overall wellbeing. The use of EE/dro-
spirenone was associated with a signiﬁ  cant reduction in 
the incidence and severity of the abdominal bloating and 
breast tenderness associated with the menstrual cycle as 
well as a positive effect on psychological well-being as 
measured by the Psychological General Well Being Index. 
These ﬁ  ndings were also conﬁ  rmed later by Sangthawan 
and Taneepanichskul (2005).
More recently, Schultz-Zehden and Boschitsch (2006) 
conducted an uncontrolled survey of 10947 women using 
the EE/drospirenone in 15 European countries and found 
that the severity of premenstrual symptoms including 
depressed mood, irritability, breast tenderness or pain, 
abdominal bloating or swelling, skin and hair problems, 
and swelling of the extremities all improved during 
treatment with the 30EE/drospirenone. Moreover, 10441 Therapeutics and Clinical Risk Management 2007:3(4) 587
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(95%) respondents were satisﬁ  ed or very satisﬁ  ed with 
the EE/drospirenone and 9016 (82%) would recommend 
it to a friend.
Rationale for COCs treatment 
of PMDD
The pathophysiology of severe PMS and PMDD is closely 
linked to an active hypothalamic-pituitary-gonadal (HPG) 
axis (Lobo and Stanczyk 1994). There is a clear relationship 
between the presence of PMS/PMDD symptomatology and 
the levels of sex steroids associated with ovulation (Freeman 
2002). The menstrual cyclicity of the ovarian hormones is 
most likely the trigger for the psychological as well as the 
somatic premenstrual symptoms. PMS and PMDD do not 
occur during pregnancy, premenarchally or in post meno-
pausal women who are not receiving hormone replacement 
therapy, or for the most part during spontaneously anovula-
tory cycles (Rapkin 2003). Moreover, Casper and Hearn 
(1990) have showed that symptoms of severe PMS may 
resolve with oopherectomy. So, researchers’ attention has 
thereby focused on ovulation suppression with COCs for the 
treatment of PMS/PMDD.
The decreasing levels of ovarian steroid hormones in the 
late luteal phase of the menstrual cycle may be accounted as 
one of probable cause of PMDD as it has been demonstrated 
that decreases in estrogens levels after ovulation may 
correlate with depressed mood during the late luteal phase 
(Watson et al 1990; Michener et al 1999).
Moreover, it has been demonstrated that estrogens 
has also been found to increase serotonergic activity by 
increasing the number of serotonergic receptors, trans-
port, and uptake (Halbreich et al 1995). As it is well 
known that serotonin levels may influence the mood, low 
estrogens levels may further explain the depressed mood 
seen in women with PMDD.
Concerning progesterone, although decreased levels 
were a long-standing hypotheses in PMDD (Dalton 1964), 
the majority of controlled trials have failed to ﬁ  nd that pro-
gesterone is superior to placebo in reducing premenstrual 
symptoms (Freeman et al 1995). In fact, the rationale for 
progesterone therapy in PMDD is not supported by studies 
of gonadal hormone levels in this disorder because they 
have showed a relative lack of consistency in results. In fact, 
whereas it has been reported that low progesterone levels 
may be present during the luteal phase (Wang et al 1996), 
some studies showed instead increased progesterone in this 
phase (Redei and Freeman 1994; Watts et al 1985) or no 
differences in PMDD women versus controls (Parry et al 
1991; Girdler et al 1993). Thus, despite the overwhelming 
evidence for an obligatory role of the gonadal hormones 
in the pathophysiology of PMDD, it is generally agreed 
that neither a deﬁ  ciency nor excess in progesterone levels 
is etiologically relevant to the disorder (Rubinow and 
Schmidt 2006).
Conversely, it has been reported that progesterone-
derived neuroactive steroid allopregnanolone may be 
involved in the pathogenesis of PMDD (Wang et al 
1996). Allopregnanolone is a metabolite of progesterone 
and is produced not only by ovary and adrenals but 
also de novo in brain (Paul and Purdy 1992). Girdler 
and colleagues (2001) observed a relationship between 
premenstrual symptom severity and allopregnanolone 
levels in the PMDD women. The results of this study 
showed a dysregulation of allopregnanolone in PMDD 
and suggested that allopregnanolone may negatively 
modulate the HPG-axis in human female subjects as it does 
in animals, and that allopregnanolone levels in PMDD 
women may inﬂ  uence severity of premenstrual symptoms 
also through GABA-A brain receptors. Moreover, has been 
reported that the allopregnanolone has the ability to cause 
augmentation of GABA(A)-mediated inhibition of 5-HT 
neurons of dorsal raphe nucleus (Stromberg et al 2005; 
Kaura et al 2006). As COCs may regulate allopregnanolone 
levels (Rapkin et al 2006), these compounds may be 
useful to treat psychic symptoms associated with PMDD 
(Sangthawan and Taneepanichskul 2005). However, 
COCs may act also on other neuroactive steroids such as 
pregnenolone sulphate (PS) and dehydroepiandrosterone 
sulphate (DHEAS) that are in general GABA-A receptor 
antagonists (Paoletti et al 2004; Dubrovsky 2005).
Taken together, these ﬁ  ndings may suggest that a pos-
sible mechanism involved in the pathogenesis of PMDD 
may be rather related to a hormonal ratio imbalance, and 
not to hormone ﬂ  uctuation (Halbreich et al 1986). In fact, a 
relative higher level of estrogens compared to relative low 
levels of progesterone may account for triggering PMDD 
symptomatology. Halbreich and colleagues (1986) found a 
signiﬁ  cant association between the rate of change of proges-
terone (increase and decrease) and to a lesser degree, rate 
of change of estrogens, and severity of symptoms. When 
progesterone and estrogens ﬂ  uctuated in different rates there 
was a signiﬁ  cant correlation between the difference of rate 
and severity of symptoms.
So, the use of COCs in the treatment of PMDD may 
restore balanced hormone levels leading to the therapeutic 
success (Rapkin et al 2006).Therapeutics and Clinical Risk Management 2007:3(4) 588
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Treatment of PMDD
with EE/drospirenone combination
In the recent years, only few placebo-controlled studies have 
examined the efﬁ  cacy of the OC formulation containing 
EE/drospirenone in the treatment of PMDD.
Freeman and colleagues (2001) conducted a double-
blind placebo-controlled trial that included 82 women with 
PMDD who were randomized to EE 30 µg/drospirenone 3 mg 
(Yasmin®) (n = 42) or placebo (n = 40). Diagnoses were made 
according with DSM-IV criteria and the primary end point 
was change from baseline in luteal phase symptom scores 
as assessed on the COPE scale. The EE/drospirenone 
combination was observed to have a positive effect on 
symptoms of PMDD, with the between-group differences 
reaching statistical signiﬁ  cance in appetite, food cravings, 
and acne (P = 0.03). Moreover, the secondary end points, 
Beck Depression Inventory and Proﬁ  le of Mood States, 
were consistent with the primary end point in that patients 
treated with the oral contraceptive and showed a numeri-
cally greater improvement from baseline compared with 
those treated with placebo.
Recently, the availability of a low-dose oral con-
traceptive with drospirenone (EE 20 µg/drospirenone 
3 mg – Yasminelle®, Yaz®) stimulated researchers to verify 
its potential efﬁ  cacy in the treatment of PMDD. In this novel 
formulation, the active hormones were administered for 
24 consecutive days (24/4) rather than the conventional 21 
days in a 28-day cycle (21/7). This new treatment platform 
is associated with greater suppression of follicle develop-
ment and a more stable hormonal status than the standard 
21/7 regimen. Therefore, together with the reported efﬁ  cacy 
of spironolactone for premenstrual symptoms, the follicular 
suppression found with a 24/4 regimen as well as the 
lower estrogens dose may be effective in the treatment of 
premenstrual symptoms.
Pearlstein and colleagues (2005), in a small, multicenter, 
double-blind, placebo-controlled crossover study, adminis-
tered EE 20 µg/drospirenone 3 mg formulation or placebo 
for 24 days in a 28-day cycle (24/4), rather than the usual 
21-day active treatment, to 64 women who were randomized 
to either study treatment for three cycles and then after a 
washout period of one treatment-free cycle switched to the 
alternate treatment. They observed that the mean decrease 
from baseline for total DRSP scores while using EE/dro-
spirenone was signiﬁ  cantly greater than for placebo with a 
positive response (ie, a score of 1 or 2 in the Clinical Global 
Impressions-Improvement scale) occurring in 61.7% and 
31.8% of subjects while taking EE/drospirenone and placebo, 
respectively. They concluded that EE/drospirenone, given 
in a 24/4 regimen, was superior to placebo for improving 
symptoms associated with PMDD.
In the same period, Yonkers and colleagues (2005) stud-
ied 450 women with symptoms of premenstrual dysphoric 
disorder randomized to either placebo or COC formulation 
containing EE 20 µg/drospirenone 3 mg. This multicenter, 
double-blind, randomized clinical trial consisted of 2 run-in 
and 3 treatment cycles with daily symptom charting with 
DRSP. At endpoint, the total DRSP symptom score in sub-
jects receiving EE/drospirenone decreased by 47% compared 
to 38% of placebo group. Moreover, overall improvement 
according to the Clinical Global Impression-Improvement 
observer-rated scale was greater for subjects receiving active 
treatment than for those in the placebo group. In conclusion, 
this placebo-controlled, double-blind study showed that the 
new drospirenone-containing COC formulation administered 
for 24 of 28 days in a cycle ameliorates symptoms associated 
with PMDD.
Adverse effects in clinical trials 
with drospirenone/EE combination 
in PMDD
The EE/drospirenone combination was generally well toler-
ated in all studies.
In the Pealstein and colleagues (2005) trial, 28 (48.2%) 
subjects using EE/drospirenone experienced adverse 
effects related to the study drug. The most frequent were 
nausea, upper respiratory infection, headache, intermen-
strual bleeding, breast pain, nervousness and asthenia. 
The discontinuation rate due to adverse effects in the 
active treatment group was 13%. One subject discontin-
ued due to an increased serum potassium levels during 
washout phase but authors classified this event as “not 
likely to be study related.”
In the trial of Yonkers and colleagues (2005) adverse 
events considered by investigators possibly related to the 
study drug occurred in 118 (51.1%) subjects receiving EE/
drospirenone. The most frequent were intermenstrual bleed-
ing, headache, nausea and breast pain. There was also one 
severe adverse event (dysplasia) considered by the investiga-
tor to be possibly related to study drug in the active-treatment 
group. 35 subjects (29.7%) in the active treatment group 
discontinued due to adverse events, but no signiﬁ  cant differ-
ence in serum potassium levels between active and placebo 
groups during the treatment period was reported.Therapeutics and Clinical Risk Management 2007:3(4) 589
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Conclusions
The results of trials evaluating the use of EE/drospirenone 
combination in the treatment of PMDD are encouraging but 
further studies are needed. In addition, a burgeoning body 
of literature has emerged that supports the role of the SSRIs 
as ﬁ  rst-line treatment of PMDD and severe PMS. Moreover, 
further complicating the issue is the fact that many somatic 
symptoms of PMDD such as breast tenderness, headache, 
bloating, and nausea can also be adverse effects of some oral 
contraceptive pills including EE/drospirenone.
So, in the authors’ opinion, to date, the EE/drospirenone 
should be taken into consideration not as a first-line 
treatment but should be reserved to SSRI-resistant subjects. 
In particular, future large, double-blind, randomized studies 
should be evaluate a comparison between SSRI and EE/
drospirenone in the treatment of PMDD to verify efﬁ  cacy 
and tolerability of these two therapeutic options.
However, the clinical efﬁ  cacy and the relative good 
tolerability of EE/drospirenone may be useful to widen the 
therapeutic spectrum of PMDD.
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